We are live on ! Find out more
TRIB

Trinity Biotech
TRIB

48 hedge funds and large institutions have $76M invested in Trinity Biotech in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.08% more ownership

Funds ownership: 3.06% → 3.15% (+0.08%)

7% less capital invested

Capital invested by funds: $81.5M → $76M (-$5.44M)

8% less funds holding

Funds holding: 52 → 48 (-4)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
48
Holders Change
-4
Holders Change %
-7.69%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
6
Increased
9
Reduced
16
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Russell Investments Group
Russell Investments Group
United Kingdom
+$3.42M
2
Morgan Stanley
Morgan Stanley
New York
+$1.58M
3
Renaissance Technologies
Renaissance Technologies
New York
+$621K
4
SM
Senvest Management
New York
+$575K
5
State Street
State Street
Massachusetts
+$543K

Top Sellers

Rank Fund Capital Flow
1
PPA
Parametric Portfolio Associates
Washington
-$1.29M
2
Boston Partners
Boston Partners
Massachusetts
-$880K
3
SCM
Stonepine Capital Management
Oregon
-$688K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$614K
5
LAM
Lapides Asset Management
Connecticut
-$599K
Name Holding Trade Value Shares
Change 		Change in
Stake
SKK
26
Shepherd Kaplan Krochuk
Massachusetts
$186K -$144K -5,587 -43%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$144K – – –
WS
28
Wedbush Securities
California
$123K -$19.3K -750 -13%
BCA
29
Benchmark Capital Advisors
New York
$122K -$71.7K -2,780 -37%
RC
30
RBF Capital
California
$77K – – –
RJA
31
Raymond James & Associates
Florida
$74K -$93K -3,606 -55%
TRCT
32
Tower Research Capital (TRC)
New York
$46K -$16.6K -643 -26%
WAS
33
WESPAC Advisors SoCal
California
$26K – – –
ECM
34
Engine Capital Management
New York
$22K +$22.1K +859 New
Bank of Montreal
35
Bank of Montreal
Ontario, Canada
$16K – – –
JCM
36
Jacobi Capital Management
Pennsylvania
$10K – – –
AG
37
Advisor Group
Arizona
$5K – – –
WT
38
Whittier Trust
California
$5K – – –
RE
39
RBC Europe
United Kingdom
$4.04K – – –
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$3K – – –
IA
41
IFP Advisors
Florida
$3K +$1.24K +48 +89%
Bank of America
42
Bank of America
North Carolina
$2K -$3.61K -140 -61%
ASN
43
Advisory Services Network
Georgia
$1K – – –
AP
44
Atwood & Palmer
Missouri
$1K – – –
DCM
45
Delpha Capital Management
New York
$1K +$541 +21 New
UBS Group
46
UBS Group
Switzerland
$1K +$1.39K +54 New
PPA
47
Parametric Portfolio Associates
Washington
– -$1.29M -46,029 Closed
SCM
48
Stonepine Capital Management
Oregon
– -$688K -24,534 Closed
KCM
49
Kennedy Capital Management
Missouri
– -$551K -19,626 Closed
JP Morgan Chase
50
JP Morgan Chase
New York
– -$405K -14,461 Closed
1
2
3

TRIB Hedge Fund Activity: Q4 2017 in Review

48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2017, worth a combined $76M — down 6.7% from $81.5M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of TRIB and 6 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 9 added.

The largest buyer was Russell Investments Group, adding an estimated $3.42M. The largest seller was Parametric Portfolio Associates, exiting entirely with an estimated $1.29M sold.

  • 48 institutional investors held Trinity Biotech (TRIB) as of Q4 2017, down from 52 in Q3 2017.
  • Funds reported $76M of Trinity Biotech stock for Q4 2017, down 6.7% quarter-over-quarter.
  • 6 funds opened new Trinity Biotech positions in Q4 2017 and 10 closed out, a net change of -4 holders.
  • The largest Trinity Biotech buyer in Q4 2017 was Russell Investments Group, an estimated $3.42M added.
  • The largest Trinity Biotech seller in Q4 2017 was Parametric Portfolio Associates, an estimated $1.29M sold.

Based on aggregated 13F filings for Q4 2017.